Cancer survivorship - Genetic susceptibility and second primary cancers: Research strategies and recommendations

Journal of the National Cancer Institute

Volumn 98, Issue 1, 2006, Pages 15-25

  Travis, Lois B ^a   Rabkin, Charles S ^a   Brown, Linda Morris ^a   Allan, James M ^b   Alter, Blanche P ^a   Ambrosone, Christine B ^c   Begg, Colin B ^d   Caporaso, Neil ^a   Chanock, Stephen ^a   DeMichele, Angela ^e   Figg, William Douglas ^a   Gospodarowicz, Mary K ^f   Hall, Eric J ^g   Hisada, Michie ^a   Inskip, Peter ^a   Kleinerman, Ruth ^a   Little, John B ^h   Malkin, David ⁱ   Ng, Andrea K ^j   Offit, Kenneth ^d   Pui, Ching Hon ^k   Robison, Leslie L ^l   Rothman, Nathaniel ^a   Shields, Peter G ^m   Strong, Louise ⁿ   Taniguchi, Toshiyasu ^o   Tucker, Margaret A ^a   Greene, Mark H ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^l UNIVERSITY OF MINNESOTA   (United States)

^m GEORGETOWN UNIVERSITY   (United States)

ⁿ UNIVERSITY OF TEXAS   (United States)

^o Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOMYCIN C;

BIOINFORMATICS; CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CARCINOGENESIS; DOCUMENTATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; EVIDENCE BASED PRACTICE; GENETIC SUSCEPTIBILITY; HUMAN; NONHUMAN; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RADIATION INJURY; SAMPLING; SOCIAL PSYCHIATRY; UNITED STATES; WORKSHOP;

ANTINEOPLASTIC AGENTS; BIOTECHNOLOGY; CARCINOGENS; CASE-CONTROL STUDIES; CLINICAL TRIALS; COHORT STUDIES; CONGRESSES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDICAL INFORMATICS; MULTICENTER STUDIES; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; REGISTRIES; SPECIMEN HANDLING; SURVIVORS; SYNDROME; UNITED STATES;

EID: 30344482555     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj001     Document Type: Note

References (144)

1. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics review. 1975-2000. Bethesda (MD): National Cancer Institute, 2003. http://seer.cancer.gov/csr/1975_2000.
2. Anonymous. Cancer survivors: Living longer, and now, better. Lancet 2004;364:2153-4.
3. Hoppe RT. Hodgkin's disease: Complications of therapy and excess mortality. Ann Oncol 1997;8:S115-8.
4. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431-9.
5. Dores GM, Schonfeld S, Chen J, Hodgson D, Fossa S, Gilbert E, et al. Long-term cause-specific mortality among 41,146 one-year survivors of Hodgkin lymphoma (HL). Proc ASCO 2005;23:562S.
6. Van't Veer LJ, Dal H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
7. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93.
8. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
9. Khoury MJ, Yang Q, Gwinn M, Little J, Flanders WD. An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genet Med 2004;6:38-47.
10. Bast RC, Hortobagyi GN. Individualized care for patients with cancer - a work in progress. N Engl J Med 2004;351:2865-9.
11. Mauch PM, Kalish LA, Marcus KC, Shulman LN, Krill E, Tarbell NJ, et al. Long-term survival in Hodgkin's disease. Cancer J Sci Am 1995; 1:33.
12. Aziz NM. Cancer survivorship research: Challenge and opportunity. J Nutr 2002;132:3494S-503S.
13. Travis LB. Therapy-related second solid tumors: Reviews and controversies. Acta Oncol 2002;41:323-33.
14. Gilbert ES, Stovall MS, Clarke EA, van Leeuwen FE, Andersson M, Glimelius B, et al. Lung cancer following treatment for Hodgkin's disease: Focus on radiation. Radiat Res 2003;159:161-73.
15. van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeck A, van den Belt-Dusebout AW, Noyon R, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995; 87:1530-7.
16. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005;23:276-92.
17. Lindor NM, Greene MH; the Mayo Familial Cancer Program. The concise handbook of family cancer syndromes. J Natl Cancer Inst 1998;90: 1039-66.
18. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Drefus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
19. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005;23:1656-63.
20. Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer 2003;97:425-40.
21. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11.
22. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-304.
23. Frebourg T, Barbier N, Yan YX, Garber JE, Dreyfus M, Fraumeni J Jr, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995;56:608-14.
24. MacGeoch C, Turner G, Bobrow LG, Barnes DM, Bishop DT, Spurr NK. Heterogeneity in Li-Fraumeni families: P53 mutation analysis and immunohistochemical staining. J Med Genet 1995;32:186-90.
25. Bachinski LL, Olufemi SE, Zhou X, Wu CC, Yip L, Shete S, et al. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res 2005;65:427-31.
26. Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001;10:83-7.
27. Malkin D, Chilton-MacNeill S, Meister LA, Sexsmith E, Diller L, Garcea RL. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Oncogene 2001;20:4441-9.
28. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 2002;9:12-6.
29. Bougeard G, Charbonnier F, Moerman A, Martin C, Ruchoux MM, Drouot N, et al. Early onset brain tumor and lymphoma in MSH2-deficient children. Am J Hum Genet 2003;72:213-6.
30. Hirsch B, Shimamura A, Moreau L, Baldinger S, Hag-alsheikh M, Bostrom B, et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 2004;103:2554-9.
31. Rowland J, Mariotto A, Aziz N, Tesauro G, Feuer EJ, Blackman D, et al. Cancer Survivorship - United States, 1971-2001. MMWR Morb Mortal Wkly Rep 2004;53:526-9.
32. Offit K, Garber J, Grady M, Geene M, Gruber S, Peshkin B, et al. American Society of Clinical Oncology curriculum: Cancer genetics and cancer predisposition testing, 2nd ed. Alexandria (VA): ASCO Publishing; 2004.
33. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. J Natl Cancer Inst Monogr 1985;68:99-112.
34. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-35.
35. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-6.
36. Thompson D, Easton DF; Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94: 1358-65.
37. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004;10:2918-21.
38. Ozcelik H, Schmocker B, Di Nicola N, Shi XH, Langer B, Moore M, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997;16:17-8.
39. Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, et al. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 2004;96:68-70.
40. Yossepowitch O, Olvera N, Satagopan JM, Huang H, Jhanwar S, Rapaport B, et al. BRCA1 and BRCA2 germline mutations in lymphoma patients. Leuk Lymph 2003;44:127-31.
41. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
42. Kauff ND, Mitra N, Robson ME, Hurley KE, Chuai S, Goldfrank D, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst 2005;97: 1382-4.
43. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-32.
44. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004;75:1131-5.
45. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency. JAMA 2005;293:1979-85.
46. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood 2003;101:822-6.
47. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34.
48. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
49. Van Leeuwen FE, Travis LB. Second cancers. In: Devita VT, et al., editors. Cancer: Principles and practice of oncology, 7th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2005. p. 2575-602.
50. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leewen FE, Clarke EA, et al. Breast cancer following radiotherapy and chemotherapy for Hodgkin's disease. JAMA 2003;290:465-75.
51. Van Leeuwen FE, Klokman WJ, Stovall M, Dahler E, van't Veer MB, Noordijk EM, et al. The role of radiation dose, chemotherapy, treatment-related ovarian ablation, and other risk factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-80.
52. Travis LB, Gospodarowicz M, Curtis RE, Clarke A, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-92.
53. Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1994;86:983-8.
54. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326:1745-51.
55. Kalow W, Ozdemir V, Tang BK, Tothfalusi L, Endrenyi L. The science of pharmacological variability: An essay. Clin Pharmacol Ther 1999; 66:445-7.
56. Dolan ME, Newbold KG, Nagasugbramanian R, Wu X, Ratain MJ, Cook EJ Jr, et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 2004;64:4353-6.
57. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A 2004;101:11809-14.
58. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
59. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003;6:71-84.
60. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
61. Felix CA. Chemotherapy-related second cancers. In: Neugut AI, Meadows AT, Robinson E, editors. Multiple primary cancers. Philadelphia (PA): Lippincott Williams & Wilkins; 1999. p. 137-64.
62. Bhatia S, Sklar C. Second cancer in survivors of childhood cancer. Nat Rev Cancer 2002;2:124-32.
63. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464-8.
64. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998;12:346-52.
65. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999;354:34-9.
66. Thomsen JB, Schroder H, Kristinsson J, Madsen B, Szumlanski C, Weinshilboum R, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Cancer 1999;86:1080-6.
67. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43.
68. Edick MJ, Cheng C, Yang W, Cheok M, Wilkinson MR, Pei D, et al. Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes Cancer 2005;42:107-16.
69. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989;16:327-36.
70. Ratain MJ. Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol 1992;19:S8-S13.
71. Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004;103:67-72.
72. Sparreboom A, Loos WJ, de Jonge MJA, Verweij J. Clinical trial design: incorporation of pharmacokinetic, pharmacodynamic and pharmacogenetic principles. In: Baguley BC, Kerr DJ, editors. Anticancer drug development. Academic Press; 2002. p. 329-51.
73. McLeod HL, King CR, Marsh S. Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. Clin Colorectal Cancer 2004;4:S43-7.
74. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: An epidemiologic review. J Natl Cancer Inst 2000;92:874-97.
75. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30.
76. Worrillow LJ, Travis LB, Smith AG, Willett EV, Rollinson S, Smith AJ, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003;9:3012-20.
77. Allan JM, Smith AG, Wheatley K, Hills RK, Travis LB, Hill DA, et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004;104:3872-7.
78. Mertens AC, Mitby PA, Radloff G, Jones IM, Perentesis J, Kiffmeyer WR, et al. XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer 2004;101:1463-72.
79. Branda RF, O'Nell JP, Sullivan LM, Albertini RJ. Factors in influencing mutation at the hprt locus in T-lymphocytes: Women treated for breast cancer. Cancer Res 1991;51:6603-7.
80. Pierce JP, Faerber S, Wright FA, Rock CL, Newman V, Flatt SW, et al. A randomized trial of the effect of a plant-based dietary patter on additional breast cancer events and survival: The Women's Healthy Eating and Living (WHEL) Study. Controlled Clin Trials 2002;23:728-56.
81. Day GL, Shore RE, Blot WJ, McLaughlin JK, Austin DF, Greenberg RS, et al. Dietary factors and second primary cancers: A follow-up of oral and pharyngeal cancer patients. Nutr Cancer 1994;21:223-32.
82. Willett WC. Diet and nutrition. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention, 2nd ed. New York (NY): Oxford University Press; 1996. p. 438-61.
83. Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, et al. Risk of new cancers following radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J Clin Oncol 2005;23:2272-9.
84. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990;250:1233-8.
85. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 1997;15:177-202.
86. Morgan SE, Kastan MB. p53 and ATM: Cell cycle, death and cancer. Annu Rev Immunol 1997;71:1-25.
87. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97:813-22.
88. Olsen JH, Hahnemann JM, Borresen-Dale AL, Tretli S, Kleinerman R, Sankila R, et al. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. Br J Cancer 2005;93:260-5.
89. Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol 1999;17:1259-66.
90. Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van T Veer MB, et al. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. Int J Radiat Biol 2000;76:693-8.
91. Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, et al. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer 2000;27:124-9.
92. Morgan WF, Day JP, Kaplan MI, McGhee EM, Limoli CL. Genomic instability induced by ionizing radiation. Radiat Res 1996;146:247-58.
93. Little JB, Nagasawa H, Pfenning H, Vetrovs H. Radiation-induced genomic instability: Delayed mutagenic and cytogenetic effects of x-rays and alpha particles. Radiat Res 1997;148:299-307.
94. Mothersil C, Seymour C. Cell-cell contact during gamma irradiation is not required to induce a bystander effect in normal human keratinocytes: evidence for release during irradiation of a signal controlling survival into the medium. Radiat Res 1998;149:256-62.
95. Nagasawa H, Little JB. Unexpected sensitivity to the induction of mutations by very low doses of alpha-particle radiation: Evidence for a bystander effect. Radiat Res 1999;152:231-6.
96. Sigurdson AJ, Jones IM. Second cancers after radiotherapy: Any evidence for radiation-induced genomic instability? Oncogene 2003;22:7018-27.
97. Daly MJ, Rioux JD, Schaffner SE, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet 2001;29:229-32.
98. Patil N, Berno AJ, Hinds DA, Barnett WA, Doshi JM, Hacker CR, et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 2001;249:1719-23.
99. Amundson SA, Bittner M, Chen YD, Trent J, Meltzer P, Fornace AJ Jr. Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses. Oncogene 1999;28: 366-72.
100. Nacht M, Dracheva T, Gao Y, Fujii T, Chen Y, Player A, et al. Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci U S A 2001;98:15203-8.
101. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000;1:48-56.
102. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: Personalized molecular medicine. JAMA 2001;286:2211-4.
103. Sreekumar A, Kyati MK, Varambally S, Barrette TR, Ghosh D, Lawrence TS, et al. Profiling of cancer cells using protein microarrays: Discovery of novel radiation-regulated proteins. Cancer Res 2001;61:7585-93.
104. Smilenov LB, Brenner DJ, Hall EJ. Modest increased sensitivity to radiation oncogenesis in ATM heterozygous versus wild-type mammalian cells. Cancer Res 2001;61:5710-3.
105. Worgul BV, Smilenov L, Brenner DJ, Junk A, Wei Z, Hall EJ. ATM heterozygous mice are more sensitive to radiation induced cataracts than are their wild-type counterparts. Proc Natl Acad Sci U S A 2002; 99:9836-3.
106. Lieberman HB, Hopkins KM, Laverty M, Chu HM. Molecular cloning and analysis of Schizosaccharomyces pombe rad9, a gene involved in DNA repair and mutagenesis. Mol Gen Genet 1992;232:367-76.
107. Lieberman HB, Hopkins KM, Nass M, Demetrick D, Davey S. A human homologue of the Schizosaccharomyces pombe rad9+ checkpoint control gene. Proc Natl Acad Sci U S A 1996;93:13890-5.
108. Hang H, Rauth SJ, Hopkins KM, Davey SK, Lieberman HB. Molecular cloning and tissue-specific expression of Mrad9, a murine orthologue of the Schizosaccharomyces pombe rad9+ checkpoint control gene. J Cell Physiol 1998;177:241-7.
109. Hopkins KM, Auerbach W, Wang XY, Hande MP, Hang H, Wolgemuth DJ, et al. Deletion of mouse Rad9 causes abnormal cellular responses to DNA damage, genomic instability and embryonic lethality. Mol Cell Biol 2004;24:7235-48.
110. Smilenov LB, Lieberman HB, Mitchell SA, Baker RA, Hopkins KM, Hall EJ. Combined haploinsufficiency for ATM and RAD9 as a factor in cell transformation, apoptosis, and DNA lesion repair dynamics. Cancer Res 2005;65:933-8.
111. Bonassi S, Hagmar L, Stromberg U, Montagud AH, Tinnerberg H, Forni A, et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res 2000;60:1619-25.
112. Zhang L, Lan Q, Guo W, Li G, Yang W, Hubbard AE, et al. Use of OctoChrome fluorescence in situ hybridization to detect specific aneuploidy among all 24 chromosomes in benzene-exposed workers. Chem Biol Interact 2005.
113. Begg CB, Zhang ZF, Sun M, Herr HW, Schantz SP. Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) Program. Am J Epidemiol 1995;142:653-65.
114. Caporaso N, Dodd K, Tucker MA. New malignancies following cancer of the respiratory tract. In: Curtis RE, Freedman DM, Ron E, Tucker P, Ries LA, Hacker D, et al., editors. New malignancies among cancer survivors: SEER Program Cancer Registries, 1973-2000. NIH Publication no. 05-5302. In Press 2005.
115. Do KA, Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK, et al. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer 2004;101:2837-42.
116. Baron JA, Rohan TE. Tobacco. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention, 2nd ed. New York (NY): Oxford University Press; 1996. p. 269-89.
117. International Agency for Research on Cancer. Alcohol drinking. Monogr Eval Carcinog Risks Hum 44. Lyon (France): International Agency for Research on Cancer; 1988.
118. Poschl G, Seitz HK. Alcohol and cancer. Alcohol Alcohol 2004;39:155-65.
119. Schottenfeld D. Alcohol as a co-factor in the etiology of cancer. Cancer 1979;43:1962-6.
120. Schottenfeld D. Multiple primary cancers. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention, 2nd edition. New York (NY): Oxford University Press; 1996. p. 1371-87.
121. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 2002;100:1989-96.
122. Ng AK, Bernardo MP, Weller E, Backstrand K, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101-8.
123. Strasser JF, Li S, Neuberg D, Silver B, Ng AK, Mauch PM. Late cardiac toxicity after mediastinal radiation therapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 2004;60:S217-8.
124. Memorial Sloan Kettering Cancer Center. Available at: http://www.mskcc.org (last accessed December 1, 2004).
125. Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM, et al. Study design and cohort characteristics of the childhood cancer survivor study: A multi-institutional collaborative project. Med Pediatr Oncol 2002;38:229-39.
126. Begg CB. Methodological and statistical considerations in the study of multiple primary cancers. In: Neugut AI, Meadows AT, Robinson E, editors. Multiple Primary Cancers. Philadelphia (PA): Lippincott Williams & Wilkins; 1999. p. 13-26.
127. Travis LB. Second cancers: Methods and recent results among patients with Hodgkin lymphoma. Proc ASCO 2004;425-33.
128. Greene MH, Harris El, Gershenson DM, Malkasian GD Jr, Melton LJ 3rd, Dembo AJ, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 1986;105:360-7.
129. Travis LB, Curtis RE, Stovall M, Holowaty EJ, Van Leeuwen FE, Glimelius B, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 1994;86:1450-7.
130. Hall EJ, Wuu S. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-8.
131. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. (131)I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-9.
132. Turner S, Maher EJ, Young T, Young J, Vaughan Hudson G. What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease. Br J Cancer 1996;73:222-7.
133. Willison DJ, Keshavjee K, Nair K, Goldsmith C, Holbrook AM. Patient consent preferences for research uses of information in electronic medical records: Interview and survey data. BMJ 2003;326:1-5.
134. Eysenbach G. Consumer health informatics. BMJ 2005;320:1713-6.
135. Bernstein JL, Langholz B, Haile RW, Bernstein L, Thomas DC, Stovall M, et al. Study design: Evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res 2004;6:R199-R214.
136. Begg CB, Berwick M. A note on the estimation of relative risks of rare genetic susceptibility factors. Cancer Epidemiol Biomarkers Prev 1997; 6:99-103.
137. Corona G, Toffoli G. High throughput screening of genetic polymorphisms by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Comb Chem High Throughput Screen 2004;7:707-25.
138. Packer BR, Yeager M, Staats B, Welch R, Crenshaw A, Kiley M, et al. SNP500Cancer: A public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2004;32:D528-32.
139. International HapMap Consortium. Integrating ethics and science in the International HapMap Project. Nat Rev Genet 2004;5:467-75.
140. Bergen AW, Haque KA, Qi Y, Beerman MB, Garcia-Closas M, Rothman N, et al. Comparison of yield and genotyping performance of multiple displacement amplification and OmniPlex whole genome amplified DNA generated from multiple DNA sources. Hum Mutat 2005;26: 262-70.
141. Buetow KH. The NCI Center for Bioinformatics (NCICB): Building a foundation for in silico biomedical research. Cancer Invest 2004;22: 117-22.
142. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
143. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RJ, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 1937-47.
144. National Cancer Institute. The nation's investment in cancer research. A plan and proposal for fiscal year 2006. Bethesda (MD): National Institutes of Health, Department of Health and Human Services, p. 1-62. http://plan.cancer.gov.